RESUMEN
Chronic cavitary pulmonary aspergillosis (CCPA) is an uncommon but serious pulmonary disease of humans, with an annual mortality rate of 10-30%. It is caused by the fungus Aspergillus fumigatus. Patients are overtly immunocompetent; however, some immunogenetic defect is likely. To investigate this, we performed a genetic association study analysing biologically plausible candidate genes in 112 CCPA patients and 279 healthy controls, and investigated gene expression in monocyte-derived macrophages from patients and controls at baseline and during stimulation with A. fumigatus. Single-nucleotide polymorphisms (SNPs) associated with CCPA were found in TLR1, CLEC7A (dectin-1), PLAT (n=2), VEGFA, and DENND1B. Macrophages from CCPA patients showed low TLR3 and TLR10 expression and high TREM1 expression at baseline, as compared with macrophages from healthy subjects, with major expression differences being seen in most Toll-like receptors (TLRs) during 9 h of co-culture with A. fumigatus. The differences in baseline expression between the healthy and CCPA groups suggest roles for TLR3 and TLR10 in susceptibility to CCPA, and the association of SNPs in PLAT (n=2), VEGFA and DENND1B supports novel roles for plasminogen activation and angiogenesis and of these genes specifically in susceptibility to CCPA.
Asunto(s)
Proteínas Adaptadoras de Señalización del Receptor del Dominio de Muerte/biosíntesis , Factores de Intercambio de Guanina Nucleótido/biosíntesis , Glicoproteínas de Membrana/biosíntesis , Aspergilosis Pulmonar/genética , Receptores Inmunológicos/biosíntesis , Activador de Tejido Plasminógeno/biosíntesis , Receptor Toll-Like 10/biosíntesis , Receptor Toll-Like 3/biosíntesis , Factor A de Crecimiento Endotelial Vascular/biosíntesis , Adulto , Anciano , Aspergillus fumigatus/aislamiento & purificación , Proteínas Adaptadoras de Señalización del Receptor del Dominio de Muerte/genética , Femenino , Expresión Génica , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Factores de Intercambio de Guanina Nucleótido/genética , Humanos , Macrófagos/inmunología , Masculino , Glicoproteínas de Membrana/genética , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Aspergilosis Pulmonar/inmunología , Receptores Inmunológicos/genética , Activador de Tejido Plasminógeno/genética , Receptor Toll-Like 10/genética , Receptor Toll-Like 3/genética , Receptor Activador Expresado en Células Mieloides 1 , Factor A de Crecimiento Endotelial Vascular/genéticaRESUMEN
Chronic cavitary pulmonary aspergillosis (CCPA) is a progressive lung condition with a 10-30% annual mortality. Although overtly immunocompetent, some immunogenetic defect in patients is likely. To investigate a possible immunogenetic defect in CCPA, we analysed biologically plausible candidate genes in 112 CCPA patients and 279 healthy controls in a genetic association study of genes involved in the post-recognition immune response to Aspergillus fumigatus. We also compared gene expression in monocyte-derived macrophages from subjects with and without disease, both at baseline and during stimulation with A. fumigatus. Compared with macrophages from healthy subjects, CCPA macrophages showed unrestrained rises in IL1A, IL1B, IL6, IRAK2 and TRAF6 throughout the experiment, and a lack of expression of TGFB1 at 9 h. Single nucleotide polymorphisms (SNPs) associated with CCPA were found in IL1B (n = 2), IL1RN and IL15 (n = 3). Uncontrolled expression of IL1 and IL6 and continuing high levels of these cytokines may result in continuing cellular influx and pro-inflammatory responses, inhibiting disease resolution and contributing to disease progression in CCPA. The association of SNPs in IL1B, IL1RN and IL15 with CCPA supports a role for the IL1 pathway, as well as implicating the IL15 gene, in susceptibility to CCPA.
Asunto(s)
Aspergillus fumigatus/inmunología , Predisposición Genética a la Enfermedad , Proteína Antagonista del Receptor de Interleucina 1/genética , Interleucina-15/genética , Interleucina-1beta/genética , Aspergilosis Pulmonar/inmunología , Adulto , Anciano , Femenino , Estudios de Asociación Genética , Humanos , Proteína Antagonista del Receptor de Interleucina 1/inmunología , Interleucina-15/inmunología , Interleucina-1beta/inmunología , Macrófagos/inmunología , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido SimpleAsunto(s)
Pruebas de Función Respiratoria/normas , Adolescente , Adulto , Niño , Femenino , Humanos , MasculinoRESUMEN
In spite of its excellent electronic properties, the use of graphene in field-effect transistors is not practical at room temperature without modification of its intrinsically semimetallic nature to introduce a bandgap. Quantum confinement effects can create a bandgap in graphene nanoribbons, but existing nanoribbon fabrication methods are slow and often produce disordered edges that compromise electronic properties. Here, we demonstrate the self-organized growth of graphene nanoribbons on a templated silicon carbide substrate prepared using scalable photolithography and microelectronics processing. Direct nanoribbon growth avoids the need for damaging post-processing. Raman spectroscopy, high-resolution transmission electron microscopy and electrostatic force microscopy confirm that nanoribbons as narrow as 40 nm can be grown at specified positions on the substrate. Our prototype graphene devices exhibit quantum confinement at low temperatures (4 K), and an on-off ratio of 10 and carrier mobilities up to 2,700 cm(2) V(-1) s(-1) at room temperature. We demonstrate the scalability of this approach by fabricating 10,000 top-gated graphene transistors on a 0.24-cm(2) SiC chip, which is the largest density of graphene devices reported to date.
RESUMEN
In children, the ratio of forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) is reportedly constant or falls linearly with age, whereas the ratio of residual volume (RV) to total lung capacity (TLC) remains constant. This seems counter-intuitive given the changes in airway properties, body proportions, thoracic shape and respiratory muscle function that occur during growth. The age dependence of lung volumes, FEV1/FVC and RV/TLC were studied in children worldwide. Spirometric data were available for 22,412 healthy youths (51.4% male) aged 4-20 yrs from 15 centres, and RV and TLC data for 2,253 youths (56.7% male) from four centres; three sets included sitting height (SH). Data were fitted as a function of age, height and SH. In childhood, FVC outgrows TLC and FEV1, leading to falls in FEV1/FVC and RV/TLC; these trends are reversed in adolescence. Taking into account SH materially reduces differences in pulmonary function within and between ethnic groups. The highest FEV1/FVC ratios occur in those shortest for their age. When interpreting lung function test results, the changing pattern in FEV1/FVC and RV/TLC should be considered. Prediction equations for children and adolescents should take into account sex, height, age, ethnic group, and, ideally, also SH.
Asunto(s)
Desarrollo del Adolescente , Desarrollo Infantil , Volumen Espiratorio Forzado , Pulmón/crecimiento & desarrollo , Pulmón/fisiología , Capacidad Vital , Adolescente , Niño , Preescolar , Femenino , Humanos , Masculino , Adulto JovenRESUMEN
Age-related reference ranges are useful for assessing growth in children. The LMS method is a popular technique for constructing growth charts that model the age-changing distribution of the measurement in terms of the median, coefficient of variation and skewness. Here the methodology is extended to references that depend on body size as well as age, by exploiting the flexibility of the generalised additive models for location, scale and shape (GAMLSS) technique. GAMLSS offers general linear predictors for each moment parameter and a choice of error distributions, which can handle kurtosis as well as skewness. A key question with such references is the nature of the age-size adjustment, additive or multiplicative, which is explored by comparing the identity link and log link for the median predictor.There are several measurements whose reference ranges depend on both body size and age. As an example, models are developed here for the first four moments of the lung function variables forced expiratory volume in 1 s (FEV(1)), forced vital capacity (FVC) and FEV(1)/FVC in terms of height and age, in a data set of 3598 children and adults aged 4 to 80 years. The results show a strong multiplicative association between spirometry, height and age, with a large and nonlinear age effect across the age range. Variability also depends nonlinearly on age and to a lesser extent on height. FEV(1) and FVC are close to normally distributed, while FEV(1)/FVC is appreciably skew to the left. GAMLSS is a powerful technique for the construction of such references, which should be useful in clinical medicine.
Asunto(s)
Envejecimiento/fisiología , Tamaño Corporal/fisiología , Pulmón/fisiología , Modelos Estadísticos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Algoritmos , Estatura/fisiología , Niño , Preescolar , Femenino , Volumen Espiratorio Forzado/fisiología , Humanos , Masculino , Persona de Mediana Edad , Valores de Referencia , Caracteres Sexuales , Espirometría , Distribuciones Estadísticas , Capacidad Vital/fisiología , Población Blanca , Adulto JovenRESUMEN
AIM: The prevalence of airway obstruction varies widely with the definition used. OBJECTIVES: To study differences in the prevalence of airway obstruction when applying four international guidelines to three population samples using four regression equations. METHODS: We collected predicted values for forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) and its lower limit of normal (LLN) from the literature. FEV(1)/FVC from 40 646 adults (including 13 136 asymptomatic never smokers) aged 17-90+years were available from American, English and Dutch population based surveys. The prevalence of airway obstruction was determined by the LLN for FEV(1)/FVC, and by using the Global Initiative for Chronic Obstructive Lung Disease (GOLD), American Thoracic Society/European Respiratory Society (ATS/ERS) or British Thoracic Society (BTS) guidelines, initially in the healthy subgroup and then in the entire population. RESULTS: The LLN for FEV(1)/FVC varied between prediction equations (57 available for men and 55 for women), and demonstrated marked negative age dependency. Median age at which the LLN fell below 0.70 in healthy subjects was 42 and 48 years in men and women, respectively. When applying the reference equations (Health Survey for England 1995-1996, National Health and Nutrition Examination Survey (NHANES) III, European Community for Coal and Steel (ECCS)/ERS and a Dutch population study) to the selected population samples, the prevalence of airway obstruction in healthy never smokers aged over 60 years varied for each guideline: 17-45% of men and 7-26% of women for GOLD; 0-18% of men and 0-16% of women for ATS/ERS; and 0-9% of men and 0-11% of women for BTS. GOLD guidelines caused false positive rates of up to 60% when applied to entire populations. CONCLUSIONS: Airway obstruction should be defined by FEV(1)/FVC and FEV(1) being below the LLN using appropriate reference equations.
Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Errores Diagnósticos , Femenino , Volumen Espiratorio Forzado/fisiología , Humanos , Masculino , Persona de Mediana Edad , Guías de Práctica Clínica como Asunto/normas , Valor Predictivo de las Pruebas , Valores de Referencia , Capacidad Vital/fisiología , Adulto JovenRESUMEN
No disponible
Asunto(s)
Masculino , Femenino , Humanos , Estándares de Referencia , Valores de Referencia , Espirometría/estadística & datos numéricos , Interpretación Estadística de Datos , Mediciones del Volumen Pulmonar/instrumentación , Mediciones del Volumen Pulmonar/métodos , Capacidad de Difusión Pulmonar/métodos , Pruebas de Función Respiratoria/instrumentación , Pruebas de Función Respiratoria/métodos , Espirometría/normas , Espirometría/tendencias , Capacidad de Difusión Pulmonar/instrumentación , Capacidad de Difusión Pulmonar/fisiología , Pruebas de Función Respiratoria/estadística & datos numéricos , Pruebas de Función Respiratoria/tendenciasRESUMEN
No disponible
Asunto(s)
Humanos , Pruebas de Función Respiratoria/normas , Enfermedades Pulmonares/diagnóstico , Selección de Paciente , Precauciones UniversalesRESUMEN
No disponible
Asunto(s)
Humanos , Espirometría/normas , Enfermedades Pulmonares/diagnóstico , Capacidad Vital/fisiología , Pruebas de Función Respiratoria/normasAsunto(s)
Algoritmos , Diagnóstico por Computador/métodos , Diagnóstico por Computador/normas , Enfermedades Pulmonares/diagnóstico , Pautas de la Práctica en Medicina/normas , Pruebas de Función Respiratoria/métodos , Pruebas de Función Respiratoria/normas , Europa (Continente) , Humanos , Estados UnidosAsunto(s)
Mediciones del Volumen Pulmonar/métodos , Estándares de Referencia , Líquido del Lavado Bronquioalveolar/química , Helio , Humanos , Técnicas de Dilución del Indicador , Pulmón/diagnóstico por imagen , Pulmón/patología , Mediciones del Volumen Pulmonar/instrumentación , Nitrógeno/análisis , Pletismografía , Guías de Práctica Clínica como Asunto , Control de Calidad , RadiografíaAsunto(s)
Obstrucción de las Vías Aéreas/diagnóstico , Enfermedades Pulmonares/diagnóstico , Pruebas de Función Respiratoria/normas , Adulto , Factores de Edad , Resistencia de las Vías Respiratorias , Femenino , Humanos , Masculino , Persona de Mediana Edad , Control de Calidad , Factores de Riesgo , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad , Espirometría/normasRESUMEN
In this article, the evidence base for botulinum-A treatment acquired in recent years is outlined, and the practicalities involved in providing this service are described. Botulinum-A is relatively new, and possible improvements for the future are considered.
Asunto(s)
Toxinas Botulínicas Tipo A/administración & dosificación , Parálisis Cerebral/tratamiento farmacológico , Fármacos Neuromusculares/administración & dosificación , Niño , Preescolar , Predicción , Humanos , Inyecciones Intramusculares , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Fourteen children aged 4 to 14 years with hip subluxation due to cerebral palsy (CP) were considered for a trial in a lying hip abduction system (Jenx Dreama, Jenx Limited, Sheffield, UK). Baseline data were recorded for 6 months, then assessments of the system were made for one year at 6 and 12 months. Assessments consisted of hip radiographs in the standard position, a parental questionnaire, and a sleep chart, which was completed by parents every Friday night during the trial. Three children could not enter the trial because of general sleep problems, and three could not complete it because they were unable to sleep with the system. One further child withdrew from the study just before the end because of unacceptable deterioration for which surgery was needed. The remaining seven children completed the trial and there was an overall improvement in rate of hip migration percentage on the right from 7% per annum in the baseline period to 4% with the system (p<0.05). On the left, changes were -3% and 0% respectively (ns). Average sleep at night changed from 9 to 9.4 hours (ns) and wakenings/night from 1 to 1.3 (ns). On the parental questionnaire, there were significant improvements noted with the system in position for seating and sleeping, ease of hip abduction for washing, and with pain reduction. This pilot study supports the use of this type of lying system but further studies are needed to establish the acceptability and efficacy of these systems, particularly in children aged 2 to 5 years when irreversible bony deformities of the hip tend to occur.
Asunto(s)
Parálisis Cerebral/rehabilitación , Equipo Médico Durable , Luxación de la Cadera/prevención & control , Articulación de la Cadera , Adolescente , Parálisis Cerebral/complicaciones , Parálisis Cerebral/fisiopatología , Niño , Preescolar , Luxación de la Cadera/etiología , Articulación de la Cadera/diagnóstico por imagen , Articulación de la Cadera/fisiopatología , Humanos , Proyectos Piloto , Estudios Prospectivos , Radiografía , Sueño , Posición Supina , Resultado del TratamientoRESUMEN
There are many potential problems with the use of serial peak expiratory flow (PEF) measurement to investigate potential occupational asthma. Among these are inaccurate and incomplete recording of results. However, PEF meters will continue to be used because of their relatively low cost and the availability of improved graphing methods and computer-assisted interpretation (OASYS-2). New technologies that automatically record PEF values and the time at which the maneuver was performed have improved the reliability of serial PEF measurements. Further, new hand-held spirometers not only record the test time but also the FEV&inf1; and FEV&inf6;, in addition to PEF. Automated assessment of maneuver quality with immediate feedback to the worker may improve test quality. The storage of raw volume-time or flow-volume curves, not yet widely available, can be used by reviewers to evaluate the quality of the maneuver on which PEF and FEV&inf1; values are based-further improving the reliability of serial measurements. Mechanical stimulators and testing waveforms are available to thoroughly test these new devices and insure that they meet the minimum ATS requirements for monitoring devices.